Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Miriam Butler"'
IKZF1 gene deletions drive resistance to cytarabine in B-cell precursor acute lymphoblastic leukemia
Autor:
Britt M. T. Vervoort, Miriam Butler, Kari J.T. Grünewald, Dorette S. van Ingen Schenau, Trisha M. Tee, Luc Lucas, Alwin D. R. Huitema, Judith M. Boer, Beat C. Bornhauser, Jean-Pierre Bourquin, Peter M. Hoogerbrugge, Vincent H.J. van der Velden, Roland P. Kuiper, Laurens T. van der Meer, Frank N. van Leeuwen
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
IKZF1-deletions occur in 10-15% of patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) and predict a poor outcome. However, the impact of IKZF1-loss on sensitivity to drugs used in contemporary treatment protocols has remained under
Externí odkaz:
https://doaj.org/article/70f5749bff5943bb9814e9df3159f0f2
Autor:
Willem P.J. Cox, Nils Evander, Dorette S. van Ingen Schenau, Gawin R. Stoll, Nadia Anderson, Lieke de Groot, Kari J.T. Grünewald, Rico Hagelaar, Miriam Butler, Roland P. Kuiper, Laurens T. van der Meer, Frank N. van Leeuwen
Publikováno v:
Haematologica, Vol 109, Iss 6 (2023)
In pediatric acute lymphoblastic leukemia (ALL), mutations/deletions affecting the TP53 gene are rare at diagnosis. However, at relapse about 12% of patients show TP53 aberrations, which are predictive of a very poor outcome. Since p53-mediated apopt
Externí odkaz:
https://doaj.org/article/986ac4b3aae24d9999fc92fcd6366f17
Autor:
Miriam Butler, Britt M.T. Vervoort, Dorette S. van Ingen Schenau, Lieneke Jongeneel, Jordy C.G. van der Zwet, René Marke, Jules P.P. Meijerink, Blanca Scheijen, Laurens T. van der Meer, Frank N. van Leeuwen
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Although long-term survival in pediatric acute lymphoblastic leukemia (ALL) currently exceeds 90%, some subgroups, defined by specific genomic aberrations, respond poorly to treatment. We previously reported that leukemias harboring deletions or muta
Externí odkaz:
https://doaj.org/article/bd62010cd4ac4cb38d96197bfa9e66ae
Autor:
Katharina Woess, Sabine Macho-Maschler, Dorette S. van Ingen Schenau, Miriam Butler, Caroline Lassnig, Daniel Valcanover, Andrea Poelzl, Katrin Meissl, Barbara Maurer, Tania Brandstoetter, Claus Vogl, Anna Koren, Stefan Kubicek, Anna Orlova, Richard Moriggl, Birgit Strobl, Veronika Sexl, Frank N. van Leeuwen, Roland P. Kuiper, Mathias Mueller
Publikováno v:
Haematologica, Vol 108, Iss 4 (2022)
Tyrosine kinase 2 (TYK2) is a member of the Janus kinase/signal transducer and activator of transcription pathway, which is central in cytokine signaling. Previously, germline TYK2 mutations have been described in two patients developing de novo T-ce
Externí odkaz:
https://doaj.org/article/16495fc0f1644407926d2399569c73ec
Publikováno v:
Stroke. 54
Background: One in 10 ischemic strokes are large hemispheric infarctions (LHI), half of which cause cerebral edema that can lead to significant mortality. Our center implemented a protocol using acute glyburide in patients with LHI to determine its s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::afd0a69b7a8f6ae53f842949e305c65a
https://doi.org/10.1161/str.54.suppl_1.tp106
https://doi.org/10.1161/str.54.suppl_1.tp106
Autor:
Beat Bornhauser, Roland P. Kuiper, Steven M. Kornblau, Britt M.T. Vervoort, Jiangyan Yu, Rico Hagelaar, Fieke W Hoff, Frank N. van Leeuwen, Dorette van Ingen Schenau, Maria Pamela Dobay, Trisha M Tee, Laurens T. van der Meer, Silvia Jenni, Jules P.P. Meijerink, Jean-Pierre Bourquin, Miriam Butler
Publikováno v:
Blood, 138(23), 2383-2395. AMER SOC HEMATOLOGY
Blood, 138, 23, pp. 2383-2395
Blood, 138, 2383-2395
Blood, 138, 23, pp. 2383-2395
Blood, 138, 2383-2395
Contains fulltext : 241347.pdf (Publisher’s version ) (Closed access) Asparaginase (ASNase) therapy has been a mainstay of acute lymphoblastic leukemia (ALL) protocols for decades and shows promise in the treatment of a variety of other cancers. To
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db47fa4b7f953cb27d3df3b78bffe81d
https://doi.org/10.1182/blood.2021011787
https://doi.org/10.1182/blood.2021011787
Publikováno v:
Journal of Oncology Pharmacy Practice. :107815522311635
Introduction Peripherally acting μ-opioid receptor antagonists (PAMORAs) are used in the treatment of opioid induced constipation without impacting the actions of opioid analgesics. Subcutaneous methylnaltrexone was one of the first PAMORAs approved
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d390e96c89a3c3c71de6898e5daae703
https://doi.org/10.1177/10781552231163540
https://doi.org/10.1177/10781552231163540
Publikováno v:
Trends in Endocrinology and Metabolism, 32, 6, pp. 367-381
Trends in Endocrinology and Metabolism, 32, 367-381
Trends in Endocrinology and Metabolism, 32, 367-381
Contains fulltext : 234011.pdf (Publisher’s version ) (Open Access) Targeting tumor cell metabolism is an attractive form of therapy, as it may enhance treatment response in therapy resistant cancers as well as mitigate treatment-related toxicities
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8df025869bd34e61ad52b873768ddc90
https://hdl.handle.net/2066/234011
https://hdl.handle.net/2066/234011
Autor:
Willem Cox, Miriam Butler, Dorette S van Ingen Schenau, Nadia Anderson, Lieke de Groot, Laurens T van der Meer, Frank N van Leeuwen
Publikováno v:
Blood. 140:3132-3133
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1be83d663c323905342b17871bfba409
https://doi.org/10.1182/blood-2022-157118
https://doi.org/10.1182/blood-2022-157118